Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$562K Sell
2,232
-423
-16% -$91K 0.08% 210
2026
Q1
$578K Buy
2,655
+119
+5% +$26.4K 0.1% 200
2025
Q4
$577K Sell
2,536
-235
-8% -$53.5K 0.1% 200
2025
Q3
$606K Sell
2,771
-342
-11% -$69.6K 0.1% 188
2025
Q2
$578K Buy
3,113
+67
+2% +$12.5K 0.11% 181
2025
Q1
$546K Buy
3,046
+163
+6% +$31.7K 0.12% 165
2024
Q4
$510K Sell
2,883
-78
-3% -$14.3K 0.11% 163
2024
Q3
$562K Buy
2,961
+142
+5% +$26.5K 0.14% 137
2024
Q2
$474K Buy
+2,819
New +$467K 0.14% 126
2023
Q4
$424K Buy
+2,739
New +$399K 0.17% 119

Other funds holding ABBV

Maia Wealth's ABBV Position: Q2 2026 in Review

Maia Wealth reduced its AbbVie (ABBV) stake by 16% in Q2 2026, selling an estimated $91K and leaving 2,232 shares worth $562K. The position accounts for 0.08% of the portfolio, ranked #210.

Maia Wealth first reported a position in ABBV in Q4 2023 and has held it in 10 quarters since. The position peaked at $606K in Q3 2025. 1,742 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Maia Wealth held 2,232 shares of AbbVie worth $562K as of Q2 2026.
  • Maia Wealth sold 423 AbbVie shares in Q2 2026, an estimated $91K.
  • AbbVie made up 0.08% of Maia Wealth's portfolio in Q2 2026, its #210 holding.
  • Maia Wealth first reported a position in AbbVie in Q4 2023 and has held it in 10 quarters since.
  • Maia Wealth's AbbVie position peaked at $606K in Q3 2025.
  • 1,742 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Maia Wealth's 13F filing for Q2 2026, filed 28 Jul 2026.